CARILION CLINIC
Antimicrobial Stewardship

Pediatric Skin and Soft Tissue Infection Treatment Guideline

Disclaimer: this guideline should not replace clinical judgement.

Degree of Severity Definition		
Severity	**Purulent**	**Non-Purulent**
Mild	Incision and drainage (I&D) only	Cellulitis/erysipelas with no focus of purulence
Moderate	Systemic signs of infection	
Severe	Failed I&D Sepsis Severely Immunocompromised	Sepsis Severely Immunocompromised Presence of bullae or sloughing

Management of <u>non-purulent</u> SSTI

Type of Infection	Organisms	Preferred Treatment	Alternative Treatment (PCN allergy)	Duration
Cellulitis and Erysipelas *Erysipelas has defined borders *Blood cultures, tissue aspirates, and skin biopsies are **NOT** routinely recommended due to low yield	**Beta-hemolytic Streptococci:** Group A – *S. pyogenes* (most common), Group B – *S. agalactiae*, Groups C, G, F ***Staphylococcus aureus* only if:** large open wound, IV drug user, penetrating trauma, active *S. aureus* infection at another site	**Mild Treatment Options (oral):** Penicillin VK 20 mg/kg/dose PO q8h (max 500 mg/dose) Amoxicillin 12.5 mg/kg/dose PO q8h (max 500 mg/dose)	Cephalexin 12.5 mg/kg/dose PO q6h (max 500 mg/dose) Clindamycin 5-10 mg/kg/dose PO q8h (max 450 mg/dose)	5 days Duration is not contingent on erythema resolution alone, may extend to 7-10 days if slow clinical improvement
		Moderate Treatment Options (intravenous): Penicillin G 60,000 to 100,000 units/kg/dose IV q6h (max 4 million units/dose) Ampicillin 25 mg/kg IV q6h (max 2000 mg/dose)	Cefazolin 33 mg/kg IV q8h (max 1000 mg/dose) Clindamycin 10 mg/kg/dose IV q8h (max 600 mg/dose)	
		Severe Treatment Options (intravenous antibiotics): See Necrotizing Fasciitis recommendations below Consider ID consult		

Last Updated: February 23, 2023

CARILION CLINIC
Antimicrobial Stewardship

Pediatric Skin and Soft Tissue Infection Treatment Guideline

Disclaimer: this guideline should not replace clinical judgement.

Impetigo * Oral antimicrobials recommended for numerous lesions or outbreaks affecting several people to decrease transmission	*S. aureus* *S. pyogenes*	**Mild:** Mupirocin (topical) twice daily **Moderate-Severe:** Empiric/MSSA Cephalexin 12.5 mg/kg PO q6h (max 500 mg/dose) MRSA suspected/confirmed. Clindamycin 5-10 mg/kg PO q8h (max 450 mg/dose)	**Moderate-Severe:** Empiric/MSSA Clindamycin 10 mg/kg PO q6h (max 600 mg/dose) MRSA SMX/TMP 5 mg TMP/kg PO q12h (max 160 mg TMP/dose) Doxycycline* 2 mg/kg PO q12h (max 100 mg/dose)	Mupirocin: 5 days All others: 7 days
Folliculitis	*S. aureus* *Pseudomonas aeruginosa* (hot tubs)	**No antimicrobials** Warm compresses Gentle cleanser		
Necrotizing Fasciitis	**Empirically:** Broad spectrum gram positive, gram negative and anaerobic coverage **Most common organisms:** Group A Streptococci (GAS) Gas Gangrene: *Clostridium perfringens, Clostridium septicum*	**Emergent surgical consultation**		
		Empiric: Vancomycin 15 mg/kg IV q6h (max 2000 mg/dose)** **PLUS** Piperacillin/tazobactam 75 mg pip/kg/dose IV q6h (max 3.375 g/dose) **Identified GAS or *Clostridium:*** Penicillin 60,000 to 100,000 units/kg/dose IV q6h (max 4 million units/dose) **PLUS** Clindamycin 10 mg/kg IV q6h (max 900 mg/dose)	**Empiric:** Linezolid <12 years: 10 mg/kg IV/PO q8h (max 600 mg/dose) ≥12 years: 600 mg IV/PO q12h **PLUS** Cefepime 50 mg/kg IV q8h (max 2000 mg/dose) **PLUS** Metronidazole 10 mg/kg IV/PO q6h (max 500 mg/dose) Meropenem 20 mg/kg IV q8h (max 1000 mg/dose)	Dependent upon surgical debridement/source control *Clindamycin used in combination for toxin binding should be **discontinued after 48-72 hours**

**Doxycycline is NOT recommended for children < 8 years old but may be used in life-threatening situations*

*** Vancomycin may be adjusted per protocol based on age and renal function*

*** Addition of clindamycin has been shown to reduce the in vitro release of streptococcal pyrogenic exotoxins, however there is still a lack of clinical prospective trials strongly recommending its use in this setting. **Addition is not needed if linezolid is part of the empiric regimen as linezolid has been shown to reduce toxin production**. Surgical intervention remains the most important treatments to manage necrotic spread.

Last Updated: February 23, 2023

CARILION CLINIC
Antimicrobial Stewardship

Pediatric Skin and Soft Tissue Infection Treatment Guideline

Disclaimer: this guideline should not replace clinical judgement.

Management of purulent SSTI				
Type of Infection	**Organisms**	**Preferred Treatment**	**Alternative Treatment (IV, PCN allergy)**	**Duration**
Abscesses (Furuncles, Carbuncles) ***For moderate/ severe, send purulent material for culture and sensitivity**	*S. aureus*	**Mild** I&D only		
		Moderate/Severe I&D plus systemic antibiotics **Empiric/MRSA:** Clindamycin 10 mg/kg IV/PO q8h (max 600 mg/dose) **MSSA:** Cephalexin 12.5 mg/kg PO q6h (max 500 mg/dose) Cefazolin 33 mg/kg IV q8h (max 1000 mg/dose)	**Empiric/MRSA:** Vancomycin 15 mg/kg IV q6h (max 2000 mg/dose)** SMX/TMP 5 mg TMP/kg IV/PO q12h (max 160 mg TMP/dose) Linezolid <12 years: 10 mg/kg IV/PO q8h (max 600 mg/dose) ≥12 years: 600 mg IV/PO q12h **MSSA:** Nafcillin 25 mg/kg IV q6h (max 2000 mg/dose)	5 days May extend to 7-10 days if slow clinical improvement
Preseptal (Periorbital) Cellulitis	*S. aureus* *S. epidermidis* *S. pyogenes* *H. influenzae* (unimmunized)	Clindamycin 10 mg/kg IV/PO q6h (max 600 mg/dose) **Rhinosinusitis/ unimmunized**: Amoxicillin/clavulanate (Formulation 7:1) 22.5 mg/kg PO q12h (max 875 mg amox/dose)	**Rhinosinusitis/unimmunized**: Cefdinir 7 mg/kg PO BID (max 300 mg/dose) OR Ceftriaxone 50-75 mg/kg IV q24h (max 2000 mg/dose)	5 days May extend to 7-10 days if slow clinical improvement

Last Updated: February 23, 2023

CARILION CLINIC Antimicrobial Stewardship

Pediatric Skin and Soft Tissue Infection Treatment Guideline

Disclaimer: this guideline should not replace clinical judgement.

Orbital Cellulitis	*S. aureus* *S. epidermidis* *S. pyogenes* **Other organisms:** *S. anginosus* Neisseria spp *M. catarrhalis* Oral anaerobes *H. influenzae* (unimmunized)	Clindamycin 10 mg/kg IV q6h (max 600 mg/dose) **PLUS** Ceftriaxone 50-75 mg/kg IV q24h (max 2000 mg/dose) **Suspected intracranial extension:** Vancomycin 20 mg/kg IV q6h (max 2000 mg/dose)** **PLUS** Ceftriaxone 50-75 mg/kg IV q24h (max 2000 mg/dose) **PLUS** Metronidazole 10 mg/kg IV/PO q8h (max 500 mg/dose)	**Suspected intracranial extension:** Vancomycin 20 mg/kg IV q6h (max 2000 mg/dose)** **PLUS** Meropenem 20 mg/kg IV q8h (max 1000 mg/dose) **OR** Levofloxacin 6 months-5 years: 10 mg/kg IV q12h (max 375 mg/dose) ≥5 years: 10 mg/kg IV q24h (max 750 mg/dose)	Minimum 10-14 days, dependent on symptom resolution

*** Vancomycin may be adjusted per protocol based on age and renal function*

Surgical Site Infections

Type of Infection	Suspected Organisms	Recommended Treatment Options
Surgical Site Infections *Culture and sensitivity for any purulent material *Short course (24-48 hours) recommended **ONLY** for patients with significant systemic response	**<48 hours:** *S. pyogenes*, Clostridium spp **>48 hours:** *S. aureus*	**Suture removal plus I&D** **MRSA** Clindamycin 10 mg/kg IV/PO q6h (max 600 mg/dose) Vancomycin 15 mg/kg IV q6h (max 2000 mg/dose)** Linezolid <12 years: 10 mg/kg IV/PO q8h (max 600 mg/dose) ≥12 years: 600 mg IV/PO q12h **MSSA** Cefazolin 33 mg/kg IV q8h (max 2000 mg/dose) Nafcillin 25 mg/kg IV q6h (max 2000 mg/dose)
	Consider adding coverage for gram negatives and anaerobes for surgeries involving: • GI tract • Perineum • Female genital tract	Ceftriaxone 50-75 mg/kg IV q24h (max 2000 mg/dose) **PLUS** Metronidazole 10 mg/kg IV/PO q8h (max 500 mg/dose) **PCN allergy:** Levofloxacin 6 months-5 years: 10 mg/kg IV q12h (max 375 mg/dose) ≥5 years: 10 mg/kg IV q24h (max 750 mg/dose) **PLUS** Metronidazole 10 mg/kg IV/PO q8h (max 500 mg/dose)

Last Updated: February 23, 2023

CARILION CLINIC Antimicrobial Stewardship

Pediatric Skin and Soft Tissue Infection Treatment Guideline

Disclaimer: this guideline should not replace clinical judgement.

Bite Wounds

Tetanus and Rabies vaccines as appropriate

For patients with wounds that do not appear infected, consider 3-5 days of pre-emptive antimicrobial therapy for:

IDSA Prophylaxis Recommendations

- **Immunocompromised or asplenic**
- **Advanced liver disease**
- **Preexisting or resultant edema of the affected area**
- **Moderate to severe injuries (especially hands or face)**
- **Injuries involving periosteum or joint capsule**

Red Book Prophylaxis Recommendations

- Moderate or severe bite wounds, especially if edema or crush injury is present
- Puncture wounds, especially if penetration of bone, tendon sheath, or joint has occurred
- Deep or surgically closed facial bite wounds
- Hand and foot bite wounds
- Genital area bite wounds
- Wounds in immunocompromised and asplenic children
- Wounds exhibiting signs of infection
- Cat bite wounds

Source of bite	Common Organisms	Antimicrobial Agents			
		Oral	Oral, PCN allergy	IV	IV, PCN allergy
Dog, cat, other mammal	Pasteurella spp *S. aureus* Streptococci Capnocytophaga spp Moraxella spp Neisseria spp Corynebacterium spp Anaerobes	Amoxicillin/ clavulanate (formulation 7:1) 12.5 mg/kg PO q12h (max 875 mg amox/ dose)	Clindamycin 10 mg/kg IV/PO q6h (max 600 mg/dose) **PLUS** Cefuroxime 15 mg/kg BID (max 500 mg/dose) **OR** Cefdinir 7 mg/kg PO BID (max 300 mg/dose) **OR** TMP/SMX 5 mg TMP/kg IV/PO q12h (max 160 mg TMP/dose)	Ampicillin-sulbactam 25 mg ampicillin/kg IV q6h (max 2000 mg ampicillin/ dose [3000 mg ampicillin-sulbactam])	Ceftriaxone 50-75 mg/kg IV q24h (max 2000 mg/dose) **OR** TMP/SMX 5 mg TMP/kg q12h (max 160 mg TMP/dose)
Human	Streptococci *S. aureus* *Eikenella corrodens* Haemophilus spp Anaerobes				
Reptile	Enteric gram-negatives Anaerobes			Ampicillin-sulbactam 25 mg ampicillin/kg IV q6h (max 2000 mg ampicillin/ D Dose [3000 mg ampicillin-sulbactam]) **PLUS** Gentamicin * 5 mg/kg IV q24h	

**Gentamicin: pharmacy consult is recommended*

Last Updated: February 23, 2023

Pediatric Skin and Soft Tissue Infection Treatment Guideline

Disclaimer: this guideline should not replace clinical judgement.

References

1. Carilion pediatric 2020 antibiogram
2. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. 2014 July; 59:10-52.
3. Hauser A, Fogarasi S. Periorbital and orbital cellulitis. *Pediatrics in Review.* 2010;31:242-249.
4. American Academy of Pediatrics. Bite Wounds. *Red Book: 2021-2024 Report of the Committee on Infectious Diseases*. American Academy of Pediatrics; 2021;169-175.
5. Goytia VK, Giannoni CM, Edwards MS. Intraorbital and intracranial extension of sinusitis: comparative morbidity. J Pediatr 2011; 158:486.
6. Danishyar A, Sergent SR. Orbital Cellulitis. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507901/
7. Anthony W. Chow, Michael S. Benninger, Itzhak Brook, et al. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults, *Clinical Infectious Diseases*, Volume 54, Issue 8, 15 April 2012, Pages e72–e112, https://doi.org/10.1093/cid/cis370